• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精神分裂症患者丘脑多巴胺 D2 受体可利用性:一项针对首发精神病且未经抗精神病药物治疗的患者的研究及荟萃分析。

Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis.

机构信息

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.

Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

出版信息

Mol Psychiatry. 2022 Feb;27(2):1233-1240. doi: 10.1038/s41380-021-01349-x. Epub 2021 Nov 10.

DOI:10.1038/s41380-021-01349-x
PMID:34759359
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9054658/
Abstract

Pharmacological and genetic evidence support a role for an involvement of the dopamine D2-receptor (D2-R) in the pathophysiology of schizophrenia. Previous molecular imaging studies have suggested lower levels of D2-R in thalamus, but results are inconclusive. The objective of the present study was to use improved methodology to compare D2-R density in whole thalamus and thalamic subregions between first-episode psychosis patients and healthy controls. Differences in thalamocortical connectivity was explored based on the D2-R results. 19 antipsychotic-naive first-episode psychosis patients and 19 age- and sex-matched healthy controls were examined using high-resolution Positron Emission Tomography (PET) and the high-affinity D2-R radioligand [C]FLB457. The main outcome was D2-R binding potential (BP) in thalamus, and it was predicted that patients would have lower binding. Diffusion tensor imaging (DTI) was performed in a subgroup of 11 patients and 15 controls. D2-R binding in whole thalamus was lower in patients compared with controls (Cohen's dz = -0.479, p = 0.026, Bayes Factor (BF) > 4). Among subregions, lower BP was observed in the ROI representing thalamic connectivity to the frontal cortex (Cohen's dz = -0.527, p = 0.017, BF > 6). A meta-analysis, including the sample of this study, confirmed significantly lower thalamic D2-R availability in patients. Exploratory analyses suggested that patients had lower fractional anisotropy values compared with controls (Cohen's d = -0.692, p = 0.036) in the inferior thalamic radiation. The findings support the hypothesis of a dysregulation of thalamic dopaminergic neurotransmission in schizophrenia, and it is hypothesized that this could underlie a disturbance of thalamocortical connectivity.

摘要

药理学和遗传学证据支持多巴胺 D2 受体(D2-R)参与精神分裂症的病理生理学。先前的分子影像学研究表明,丘脑的 D2-R 水平较低,但结果尚无定论。本研究的目的是使用改进的方法来比较首发精神病患者和健康对照者全丘脑和丘脑亚区的 D2-R 密度。根据 D2-R 结果探讨了丘脑皮质连接的差异。使用高分辨率正电子发射断层扫描(PET)和高亲和力 D2-R 放射性配体 [C]FLB457 检查了 19 名抗精神病药物初发精神分裂症患者和 19 名年龄和性别匹配的健康对照者。主要结果是丘脑的 D2-R 结合潜能(BP),预计患者的结合会降低。在 11 名患者和 15 名对照者的亚组中进行了弥散张量成像(DTI)。与对照组相比,患者的全丘脑 D2-R 结合降低(Cohen's dz=-0.479,p=0.026,贝叶斯因子(BF)>4)。在亚区中,与额叶皮质连接的丘脑 ROI 中的 BP 较低(Cohen's dz=-0.527,p=0.017,BF>6)。包括本研究样本在内的一项荟萃分析证实,患者的丘脑 D2-R 可用性明显降低。探索性分析表明,与对照组相比,患者的下丘脑辐射的各向异性分数值较低(Cohen's d=-0.692,p=0.036)。研究结果支持了精神分裂症中丘脑多巴胺能神经传递失调的假说,并且假设这可能是丘脑皮质连接紊乱的基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c38a/9054658/850985184386/41380_2021_1349_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c38a/9054658/a2b21024b720/41380_2021_1349_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c38a/9054658/abb5661740cb/41380_2021_1349_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c38a/9054658/850985184386/41380_2021_1349_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c38a/9054658/a2b21024b720/41380_2021_1349_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c38a/9054658/abb5661740cb/41380_2021_1349_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c38a/9054658/850985184386/41380_2021_1349_Fig3_HTML.jpg

相似文献

1
Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis.精神分裂症患者丘脑多巴胺 D2 受体可利用性:一项针对首发精神病且未经抗精神病药物治疗的患者的研究及荟萃分析。
Mol Psychiatry. 2022 Feb;27(2):1233-1240. doi: 10.1038/s41380-021-01349-x. Epub 2021 Nov 10.
2
Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.未服用抗精神病药物的精神分裂症患者在选择性多巴胺D2/3受体阻断6周前后的额束与精神症状
J Psychiatry Neurosci. 2016 Mar;41(2):133-41. doi: 10.1503/jpn.150030.
3
Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis.精神分裂症患者皮质应激调节紊乱,但精神病高危临床患者无此现象。
Brain. 2018 Jul 1;141(7):2213-2224. doi: 10.1093/brain/awy133.
4
Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.在执行认知任务时,处于精神分裂症临床高风险、未经抗精神病药物治疗的患者和健康对照组人群的多巴胺 D2 和 D3 结合情况。
J Psychiatry Neurosci. 2013 Mar;38(2):98-106. doi: 10.1503/jpn.110181.
5
D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia.精神分裂症患者丘脑和皮质中[F-18]氟哌利多与D2/D3多巴胺受体的结合情况。
Schizophr Res. 2006 Jul;85(1-3):232-44. doi: 10.1016/j.schres.2006.03.042. Epub 2006 May 19.
6
Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia.精神分裂症患者丘脑亚区域中多巴胺D(2)受体结合水平较低。
Am J Psychiatry. 2004 Jun;161(6):1016-22. doi: 10.1176/appi.ajp.161.6.1016.
7
The relationship between excitement symptom severity and extrastriatal dopamine D receptor availability in patients with schizophrenia: a high-resolution PET study with [F]fallypride.精神分裂症患者兴奋症状严重程度与纹状体外多巴胺 D 受体可用性的关系:一项使用 [F]fallypride 的高分辨率 PET 研究。
Eur Arch Psychiatry Clin Neurosci. 2018 Sep;268(6):529-540. doi: 10.1007/s00406-017-0821-y. Epub 2017 Jun 16.
8
Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.精神分裂症患者首次抗精神病药物治疗前后额叶D2/3受体可用性:与认知功能和精神病理学的关系。
Int J Neuropsychopharmacol. 2016 Apr 29;19(5). doi: 10.1093/ijnp/pyw006. Print 2016 May.
9
Extrastriatal dopamine D receptors and cortical grey matter volumes in antipsychotic-naïve schizophrenia patients before and after initial antipsychotic treatment.抗精神病药物初治的精神分裂症患者纹状体外多巴胺 D2 受体与皮质灰质体积的变化。
World J Biol Psychiatry. 2017 Oct;18(7):539-549. doi: 10.1080/15622975.2016.1237042. Epub 2016 Oct 26.
10
Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457.初发未用药精神分裂症患者丘脑D2/D3受体结合减少:一项使用[11C]FLB 457的PET研究
Int J Neuropsychopharmacol. 2003 Dec;6(4):361-70. doi: 10.1017/S1461145703003699.

引用本文的文献

1
Hypermethylation and increased expression of the DRD2 gene in schizophrenia.精神分裂症中DRD2基因的高甲基化与表达增加
BMC Psychiatry. 2025 Jul 15;25(1):702. doi: 10.1186/s12888-025-07154-y.
2
Evidence for direct dopaminergic connections between substantia nigra pars compacta and thalamus in young healthy humans.健康年轻人中黑质致密部与丘脑之间存在直接多巴胺能连接的证据。
Front Neural Circuits. 2025 Jan 9;18:1522421. doi: 10.3389/fncir.2024.1522421. eCollection 2024.
3
Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D receptor availability in healthy individuals.

本文引用的文献

1
Kinfitr - an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability.Kinfitr - 一种用于可重复PET建模的开源工具:重测信度的验证与评估
EJNMMI Res. 2020 Jul 8;10(1):77. doi: 10.1186/s13550-020-00664-8.
2
Exploring white matter microstructure and the impact of antipsychotics in adolescent-onset psychosis.探索青少年发病型精神病中的脑白质微观结构及其抗精神病药物的影响。
PLoS One. 2020 May 29;15(5):e0233684. doi: 10.1371/journal.pone.0233684. eCollection 2020.
3
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats.
难治性精神分裂症的遗传风险以及健康个体中多巴胺合成能力和D受体可用性的相应变化。
Mol Psychiatry. 2025 Jun;30(6):2645-2652. doi: 10.1038/s41380-024-02873-2. Epub 2024 Dec 27.
4
PET-MRI Applications and Future Prospects in Psychiatry.PET-MRI在精神病学中的应用及未来前景。
J Magn Reson Imaging. 2025 Feb;61(2):568-578. doi: 10.1002/jmri.29471. Epub 2024 Jun 5.
5
Alterations in type 2 dopamine receptors across neuropsychiatric conditions: A large-scale PET cohort.2 型多巴胺受体在神经精神疾病中的改变:一项大型 PET 队列研究。
Neuroimage Clin. 2024;41:103578. doi: 10.1016/j.nicl.2024.103578. Epub 2024 Feb 13.
6
Spatial and Temporal Abnormalities of Spontaneous Fixational Saccades and Their Correlates With Positive and Cognitive Symptoms in Schizophrenia.精神分裂症中自发性固视性眼球跳动的时空异常及其与阳性和认知症状的相关性。
Schizophr Bull. 2024 Jan 1;50(1):78-88. doi: 10.1093/schbul/sbad039.
7
Raclopride-Molecularly Imprinted Polymers: A Promising Technology for Selective [C]Raclopride Purification.雷氯必利-分子印迹聚合物:一种用于选择性纯化[C]雷氯必利的有前景的技术。
Materials (Basel). 2023 Jan 27;16(3):1091. doi: 10.3390/ma16031091.
8
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics.D-氨基酸治疗抵抗性精神分裂症的合理性和转化意义:从神经生物学到临床。
Biomolecules. 2022 Jun 29;12(7):909. doi: 10.3390/biom12070909.
9
Application of positron emission tomography in psychiatry-methodological developments and future directions.正电子发射断层扫描在精神病学中的应用——方法学的发展与未来方向。
Transl Psychiatry. 2022 Jun 14;12(1):248. doi: 10.1038/s41398-022-01990-2.
突触密度标志物 SV2A 在精神分裂症患者中减少,而在大鼠中不受抗精神病药物影响。
Nat Commun. 2020 Jan 14;11(1):246. doi: 10.1038/s41467-019-14122-0.
4
Validity and reliability of extrastriatal [C]raclopride binding quantification in the living human brain.活体人脑中外侧纹状体 [C]raclopride 结合定量的有效性和可靠性。
Neuroimage. 2019 Nov 15;202:116143. doi: 10.1016/j.neuroimage.2019.116143. Epub 2019 Aug 29.
5
Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning.小胶质细胞导致精神分裂症患者来源的突触修剪模型中突触消除增加。
Nat Neurosci. 2019 Mar;22(3):374-385. doi: 10.1038/s41593-018-0334-7. Epub 2019 Feb 4.
6
The role of striatal dopamine D receptors in cognitive performance in drug-free patients with schizophrenia.纹状体多巴胺 D 受体在未经药物治疗的精神分裂症患者认知表现中的作用。
Psychopharmacology (Berl). 2018 Aug;235(8):2221-2232. doi: 10.1007/s00213-018-4916-6. Epub 2018 May 1.
7
Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures.精神分裂症中的突触缺失:突触蛋白和信使 RNA 测量的荟萃分析和系统综述。
Mol Psychiatry. 2019 Apr;24(4):549-561. doi: 10.1038/s41380-018-0041-5. Epub 2018 Mar 6.
8
Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group.广泛性精神分裂症患者的脑白质微观结构差异:来自 ENIGMA 精神分裂症弥散张量成像工作组的 4322 名个体的研究结果。
Mol Psychiatry. 2018 May;23(5):1261-1269. doi: 10.1038/mp.2017.170. Epub 2017 Oct 17.
9
The Human Thalamus Is an Integrative Hub for Functional Brain Networks.人类丘脑是功能性脑网络的整合枢纽。
J Neurosci. 2017 Jun 7;37(23):5594-5607. doi: 10.1523/JNEUROSCI.0067-17.2017. Epub 2017 Apr 27.
10
Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [C]SCH-23390.皮质 PET 分析中基于体素和基于表面的归一化和平滑技术的可靠性:使用 [C]SCH-23390 的测试-重测分析。
Neuroimage. 2017 Jul 15;155:344-353. doi: 10.1016/j.neuroimage.2017.04.031. Epub 2017 Apr 15.